PF4V1

Summary

PF4V1 (platelet factor 4 variant 1, HGNC:8862) is a protein-coding gene on chromosome 4q13.3, encoding Platelet factor 4 variant (P10720). Inhibitor of angiogenesis.

The protein encoded by this gene is a chemokine that is highly similar to platelet factor 4. The encoded protein displays a strong antiangiogenic function and is regulated by chemokine (C-X-C motif) receptor 3. This protein also impairs tumor growth and can protect against blood-retinal barrier breakdown in diabetes patients.

Source: NCBI Gene 5197 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 26 total
• MANE Select transcript: NM_002620

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8862
Approved symbol	PF4V1
Name	platelet factor 4 variant 1
Location	4q13.3
Locus type	gene with protein product
Status	Approved
Aliases	SCYB4V1, CXCL4V1, CXCL4L1
Ensembl gene	ENSG00000109272
Ensembl biotype	protein_coding
OMIM	173461
Entrez	5197

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000226524

RefSeq mRNA: 1 — MANE Select: NM_002620 NM_002620

CCDS: CCDS3561

Canonical transcript exons

ENST00000226524 — 3 exons

Exon	Start	End
ENSE00000721941	73853296	73853462
ENSE00001077827	73854035	73854483
ENSE00002462427	73853783	73853909

Expression profiles

Bgee: expression breadth ubiquitous, 117 present calls, max score 96.31.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.1402 / max 527.0811, expressed in 116 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
48225	2.1402	116

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	96.31	gold quality
mononuclear cell	CL:0000842	95.83	gold quality
leukocyte	CL:0000738	94.42	gold quality
blood	UBERON:0000178	78.53	gold quality
granulocyte	CL:0000094	73.00	gold quality
palpebral conjunctiva	UBERON:0001812	68.10	gold quality
bone marrow	UBERON:0002371	65.64	gold quality
spleen	UBERON:0002106	65.55	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	63.11	gold quality
trabecular bone tissue	UBERON:0002483	62.51	silver quality
bone marrow cell	CL:0002092	61.80	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	59.16	gold quality
bronchial epithelial cell	CL:0002328	57.93	silver quality
epithelium of bronchus	UBERON:0002031	57.14	silver quality
decidua	UBERON:0002450	56.55	gold quality
bronchus	UBERON:0002185	56.53	silver quality
lower lobe of lung	UBERON:0008949	55.90	silver quality
metanephros cortex	UBERON:0010533	54.06	gold quality
jejunal mucosa	UBERON:0000399	53.94	gold quality
duodenum	UBERON:0002114	53.22	gold quality
hair follicle	UBERON:0002073	52.43	gold quality
metanephros	UBERON:0000081	51.71	gold quality
adult mammalian kidney	UBERON:0000082	51.04	gold quality
cranial nerve II	UBERON:0000941	50.93	silver quality
right lung	UBERON:0002167	50.57	gold quality
cortex of kidney	UBERON:0001225	50.45	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
quadriceps femoris	UBERON:0001377	50.18	gold quality
nasal cavity mucosa	UBERON:0001826	50.18	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9221	yes	19.90
E-HCAD-1	yes	8.39
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RUNX1

miRNA regulators (miRDB)

48 targeting PF4V1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-548AG	99.77	69.25	1492
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-6885-3P	99.75	70.36	3187

Literature-anchored findings (GeneRIF, showing 13)

• The study determines the binding parameters of CXCL4 and CXCL4L1 for heparin, heparan sulfate, and chondroitin sulfate B. (PMID:20688960)
• CXCL4L1 may act angiostatically causing random endothelial cell locomotion, disturbing directed migration towards angiogenic chemokines, serving as a homeostatic chemokine with moderate structural distinction yet different functional profile from CXCL4. (PMID:20961394)
• both CXCR3A and CXCR3B are implicated in the chemotactic and vascular effects of CXCL4L1. (PMID:20980681)
• Current knowledge on the role of CXCL4/PF-4 and CXCL4L1/PF-4var in physiological and pathological processes. (PMID:21111666)
• PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function (PMID:22384011)
• Structural insight into the novel functional properties of human CXCL4L1. (PMID:23536183)
• Fibstatin and CXCL4L1 cooperate to inhibit endothelial cell proliferation, migration and tubulogenesis in vitro. (PMID:23747987)
• fibstatin and CXCL4L1 have cooperative roles in inhibition of tumor invasion in lymph nodes (PMID:23747987)
• CXCL4 and CXCL4L1 activated p38 MAPK, as well as Src kinase within 30 and 5 min, respectively. Extracellular signal-regulated kinase (ERK) phosphorylation occurred in activated lymphocytes. (PMID:24469069)
• CXCL4 and CXCL4L1 shift the angiogenic/angiostatic balance in favor of angiostasis. CXCL4L1 in particular was found to be a more potent angiostatic, anti-tumoral and anti-metastatic chemokine, which was verified in different in vivo models. (PMID:29903575)
• CXCL4L1 promoter variants may protect against the development of renal inflammation in diabetes by increasing CXCL4L1 expression, which in turn activates the anti-inflammatory SMAD7 and IkappaBalpha factors in mesangial cells. (PMID:30593538)
• Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells. (PMID:35054772)
• Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation. (PMID:36094626)

Cross-species orthologs

0 orthologs

Paralogs (12): CXCL2 (ENSG00000081041), CXCL6 (ENSG00000124875), CXCL9 (ENSG00000138755), CXCL13 (ENSG00000156234), CXCL3 (ENSG00000163734), CXCL5 (ENSG00000163735), PPBP (ENSG00000163736), PF4 (ENSG00000163737), CXCL1 (ENSG00000163739), CXCL10 (ENSG00000169245), CXCL11 (ENSG00000169248), CXCL8 (ENSG00000169429)

Protein

Protein identifiers

Platelet factor 4 variant — P10720 (reviewed: P10720)

Alternative names: C-X-C motif chemokine 4 variant, CXCL4L1, PF4alt, PF4var1

All UniProt accessions (1): P10720

UniProt curated annotations — full annotation on UniProt →

Function. Inhibitor of angiogenesis. Inhibitor of endothelial cell chemotaxis (in vitro).

Subunit / interactions. Homotetramer.

Subcellular location. Secreted.

Post-translational modifications. The N-terminal processed forms of platelet factor 4 variant seems to be produced by proteolytic cleavage. The most abundant form is Platelet factor 4 variant(5-74).

Miscellaneous. Binding to heparin is much weaker than in the close homolog PF4/CXCL4.

Similarity. Belongs to the intercrine alpha (chemokine CxC) family.

RefSeq proteins (1): NP_002611* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001089	Chemokine_CXC	Family
IPR001811	Chemokine_IL8-like_dom	Domain
IPR018048	Chemokine_CXC_CS	Conserved_site
IPR033899	CXC_Chemokine_domain	Domain
IPR036048	Interleukin_8-like_sf	Homologous_superfamily
IPR039809	Chemokine_b/g/d	Family

Pfam: PF00048

UniProt features (17 total): strand 5, chain 4, helix 2, disulfide bond 2, signal peptide 1, turn 1, binding site 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4HSV	X-RAY DIFFRACTION	2.08

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P10720-F1	77.18	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 95–101

Disulfide bonds (2): 44–70, 46–86

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-9769739	Regulation of clotting cascade
R-HSA-140875

MSigDB gene sets: 96 (showing top): GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CELL_CHEMOTAXIS, GOBP_INFLAMMATORY_RESPONSE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_LEUKOCYTE_CHEMOTAXIS, chr4q13, GOBP_TAXIS, GOBP_LEUKOCYTE_MIGRATION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_GRANULOCYTE_MIGRATION, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_HUMORAL_IMMUNE_RESPONSE

GO Biological Process (8): inflammatory response (GO:0006954), neutrophil chemotaxis (GO:0030593), antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844), cellular response to lipopolysaccharide (GO:0071222), chemotaxis (GO:0006935), defense response (GO:0006952), immune response (GO:0006955), signal transduction (GO:0007165)

GO Molecular Function (5): chemokine activity (GO:0008009), heparin binding (GO:0008201), CXCR chemokine receptor binding (GO:0045236), cytokine activity (GO:0005125), protein binding (GO:0005515)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Hemostasis	1
Coagulation pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
chemokine receptor binding	2
defense response	1
granulocyte chemotaxis	1
neutrophil migration	1
antimicrobial humoral response	1
response to lipopolysaccharide	1
cellular response to molecule of bacterial origin	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
response to chemical	1
taxis	1
response to stress	1
immune system process	1
response to stimulus	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cytokine activity	1
cell chemotaxis	1
glycosaminoglycan binding	1
sulfur compound binding	1
receptor ligand activity	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

940 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PF4V1	CXCR3	P49682	977
PF4V1	CCL5	P13501	927
PF4V1	SELP	P16109	890
PF4V1	VWF	P04275	845
PF4V1	SERPINC1	P01008	803
PF4V1	FN1	P02751	770
PF4V1	CXCL10	P02778	751
PF4V1	CXCL9	Q07325	740
PF4V1	PLG	P00747	730
PF4V1	CCL1	P22362	707
PF4V1	FCGR2A	P12318	696
PF4V1	THBS1	P07996	689
PF4V1	ITGAM	P11215	688
PF4V1	F3	P13726	664
PF4V1	APOH	P02749	654

IntAct

28 interactions, top by confidence:

A	B	Type	Score
PF4V1	CXCL12	psi-mi:“MI:0407”(direct interaction)	0.560
CXCL12	PF4V1	psi-mi:“MI:0407”(direct interaction)	0.560
PF4V1	CCL19	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CCL21	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CCL22	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CCL25	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CCL26	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CCL27	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CCL28	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	XCL1	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	XCL2	psi-mi:“MI:0407”(direct interaction)	0.440
CCL4L1	PF4V1	psi-mi:“MI:0407”(direct interaction)	0.440
CCL11	PF4V1	psi-mi:“MI:0407”(direct interaction)	0.440
CCL21	PF4V1	psi-mi:“MI:0407”(direct interaction)	0.440
CCL25	PF4V1	psi-mi:“MI:0407”(direct interaction)	0.440
XCL1	PF4V1	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL11	PF4V1	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CXCL11	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CXCL13	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	UBA52	psi-mi:“MI:0915”(physical association)	0.400
PF4V1	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
ALB	SH3BP5	psi-mi:“MI:0914”(association)	0.350
SCN2A	IGLL5	psi-mi:“MI:0914”(association)	0.350
PF4V1	ATG9A	psi-mi:“MI:0914”(association)	0.350

BioGRID (27): PF4V1 (Affinity Capture-MS), UBA52 (Proximity Label-MS), HIST1H2BH (Proximity Label-MS), PF4V1 (Reconstituted Complex), PF4V1 (Reconstituted Complex), PF4V1 (Reconstituted Complex), PF4V1 (Reconstituted Complex), PF4V1 (Reconstituted Complex), PF4V1 (Reconstituted Complex), CCL19 (Reconstituted Complex), CCL21 (Reconstituted Complex), CCL22 (Reconstituted Complex), CCL25 (Reconstituted Complex), CCL26 (Reconstituted Complex), CCL27 (Reconstituted Complex)

ESM2 similar proteins: A0A0R4INB9, A9QWP9, B0R191, K7XWG4, O43927, O55038, O62812, P02776, P02778, P06765, P10145, P10146, P10720, P17515, P18340, P19874, P22362, P26894, P36925, P41324, P43030, P46653, P48298, P48973, P49113, P67813, P67814, P78556, P79255, P80325, P82943, P97545, P97884, P97885, Q03366, Q07325, Q09141, Q102R3, Q2KIQ8, Q5KSV9

Diamond homologs: A0A0R4INB9, A9QWP9, B0R191, O46675, O46676, O46677, O46678, O55235, O62812, P02775, P02776, P02778, P06765, P08317, P09340, P09341, P10145, P10720, P10889, P12850, P14095, P17515, P18340, P19874, P19875, P19876, P22952, P26894, P30034, P30348, P30782, P36925, P41324, P42830, P43030, P46653, P47854, P48973, P49113, P50228

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 22 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Chemokine receptors bind chemokines	13	128.1×	6e-24
Class A/1 (Rhodopsin-like receptors)	8	31.2×	5e-09
Peptide ligand-binding receptors	8	31.2×	5e-09
GPCR ligand binding	8	27.0×	1e-08
G alpha (i) signalling events	10	20.5×	1e-09
Signaling by GPCR	9	19.0×	1e-08
GPCR downstream signalling	7	16.0×	6e-06

GO biological processes:

GO term	Partners	Fold	FDR
eosinophil chemotaxis	7	233.1×	3e-14
chemokine-mediated signaling pathway	13	191.5×	5e-26
antimicrobial humoral immune response mediated by antimicrobial peptide	12	88.4×	1e-19
cell chemotaxis	9	75.8×	5e-14
neutrophil chemotaxis	5	64.9×	2e-07
chemotaxis	9	55.6×	7e-13
response to virus	5	32.7×	6e-06
positive regulation of cell migration	10	28.1×	2e-11

Disease & clinical

Clinical variants and AI predictions

ClinVar

26 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

220 predictions. Top by Δscore:

Variant	Effect	Δscore
4:73853460:GAG:G	donor_gain	1.0000
4:73853461:AGGT:A	donor_loss	1.0000
4:73853463:G:A	donor_loss	1.0000
4:73853463:G:GG	donor_gain	1.0000
4:73853781:A:AG	acceptor_gain	1.0000
4:73853781:AGCT:A	acceptor_gain	1.0000
4:73853782:G:GT	acceptor_gain	1.0000
4:73853782:GC:G	acceptor_gain	1.0000
4:73853782:GCT:G	acceptor_gain	1.0000
4:73853782:GCTG:G	acceptor_gain	1.0000
4:73853782:GCTGA:G	acceptor_gain	1.0000
4:73853905:CTCAT:C	donor_gain	1.0000
4:73853909:TGT:T	donor_loss	1.0000
4:73853910:G:GA	donor_loss	1.0000
4:73853910:G:GG	donor_gain	1.0000
4:73853912:GA:G	donor_loss	1.0000
4:73853464:T:A	donor_loss	0.9900
4:73853784:T:A	acceptor_gain	0.9900
4:73853866:G:GT	donor_gain	0.9900
4:73853906:TCAT:T	donor_gain	0.9900
4:73853907:CAT:C	donor_gain	0.9900
4:73853908:AT:A	donor_gain	0.9900
4:73853913:AG:A	donor_loss	0.9900
4:73853914:G:C	donor_loss	0.9900
4:73854031:CCAG:C	acceptor_gain	0.9900
4:73854033:A:AG	acceptor_gain	0.9900
4:73854034:G:GG	acceptor_gain	0.9900
4:73854034:GA:G	acceptor_gain	0.9900
4:73854034:GAGCC:G	acceptor_gain	0.9900
4:73854029:TGCCA:T	acceptor_loss	0.9800

AlphaMissense

666 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:73854037:C:A	A77D	0.959
4:73853890:T:A	C70S	0.937
4:73853891:G:C	C70S	0.937
4:73854063:T:A	C86S	0.928
4:73854064:G:C	C86S	0.928
4:73853818:T:A	C46S	0.923
4:73853819:G:C	C46S	0.923
4:73853890:T:C	C70R	0.916
4:73853812:T:A	C44S	0.907
4:73853813:G:C	C44S	0.907
4:73854063:T:C	C86R	0.907
4:73854067:T:C	L87S	0.900
4:73853891:G:A	C70Y	0.878
4:73854065:C:G	C86W	0.877
4:73853906:T:C	L75P	0.875
4:73853812:T:C	C44R	0.874
4:73854064:G:A	C86Y	0.863
4:73853890:T:G	C70G	0.862
4:73853818:T:C	C46R	0.858
4:73854052:G:T	G82V	0.858
4:73853892:C:G	C70W	0.854
4:73853855:T:C	I58T	0.842
4:73853855:T:G	I58S	0.840
4:73854036:G:C	A77P	0.839
4:73853819:G:A	C46Y	0.835
4:73854063:T:G	C86G	0.812
4:73853904:A:C	Q74H	0.803
4:73853904:A:T	Q74H	0.803
4:73853855:T:A	I58N	0.799
4:73853891:G:T	C70F	0.788

dbSNP variants (sampled 300 via entrez): RS1000494433 (4:73854948 A>C,G), RS1000633386 (4:73854704 C>T), RS1003176557 (4:73852422 T>C), RS1004772460 (4:73854296 T>C), RS1005140536 (4:73851858 C>A,T), RS1005188210 (4:73854836 A>G), RS1006300099 (4:73851328 C>G,T), RS1006743023 (4:73851533 A>G), RS1007156677 (4:73854381 T>A,C), RS1008121288 (4:73851763 G>A), RS1009262247 (4:73852787 G>T), RS1009314584 (4:73852465 G>A), RS1011900158 (4:73852066 G>T), RS1014763759 (4:73854303 A>G), RS1014813902 (4:73851863 T>C)

Disease associations

OMIM: gene MIM:173461 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001725_78	Inflammatory bowel disease	3.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Asian ginseng	decreases reaction, increases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
chromium hexavalent ion	increases expression	1
CGP 52608	increases reaction, affects binding	1
thrombin receptor-activating peptide SFLLRNPNDKY	decreases reaction, increases secretion	1
K 7174	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Aspirin	decreases reaction, increases secretion	1
Benzo(a)pyrene	increases expression	1
Diethylhexyl Phthalate	decreases reaction, increases expression	1
Malathion	decreases expression	1
Tamoxifen	affects expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases expression	1
Cyclosporine	decreases expression	1
beta-Naphthoflavone	increases expression	1
Particulate Matter	decreases expression, increases abundance	1
Coal Ash	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.